2-碘-3-氟硝基苯 | 122455-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-碘-3-氟硝基苯
• 中文别名: 3-氟2-碘-硝基苯；3-氟-2-碘硝基苯
• 英文名称: 1-Fluoro-3-nitroiodobenzene
• 英文别名: 2-iodo-3-nitrofluorobenzene；2-iodo-3-fluoronitrobenzene；3-fluoro-2-iodonitrobenzene；1-Fluoro-2-iodo-3-nitrobenzene
• CAS: 122455-36-1
• 化学式: C₆H₃FINO₂
• 分子量: 266.998
• InChiKey: XADPCRFTWLAXEV-UHFFFAOYSA-N

物化性质

• 沸点：
  283.1±25.0 °C(Predicted)
• 密度：
  2.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2904909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Iodo-3-fluoronitrobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Iodo-3-fluoronitrobenzene
CAS number: 122455-36-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3FINO2
Molecular weight: 267

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-碘-3-氟硝基苯 在 盐酸 、 tin(ll) chloride 、 sodium hydroxide 作用下， 以 水 为溶剂， 以90%的产率得到3-氟-2-碘苯胺
  参考文献：
  名称：

  Compounds and Uses Thereof - 848

  摘要：

  本发明涉及具有下面结构式I的新化合物：及其药用盐、互变异构体或体内水解前体，其组合物和使用方法，其中R1、R2、R3、R4、R5和R6在规范中定义。这些新化合物提供了治疗或预防焦虑症、精神分裂症、认知障碍和/或情绪障碍的方法。

  公开号：

  US20080318943A1
• 作为产物：
  描述：

  2-fluoro-6-nitrophenyl trifluoromethanesulfonate 在 lithium iodide 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以81%的产率得到2-碘-3-氟硝基苯
  参考文献：
  名称：

  Compounds and Uses Thereof

  摘要：

  该发明涉及具有如下结构式I的新化合物及其药用盐、互变异构体或体内可水解前体，以及其使用的组合物和方法。这些新化合物可用于治疗或预防焦虑障碍、认知障碍和/或情绪障碍。

  公开号：

  US20070142328A1

文献信息

• Approaches to the Synthesis of 2,3-Dihaloanilines. Useful Precursors of 4-Functionalized-1<i>H</i>-indoles
  作者：Verónica Guilarte、M. Pilar Castroviejo、Patricia García-García、Manuel A. Fernández-Rodríguez、Roberto Sanz

  DOI：10.1021/jo200406f

  日期：2011.5.6

  2,3-Dihaloanilines have been proved as useful starting materials for synthesizing 4-halo-1H-indoles. Subsequent or in situ functionalization of the prepared haloindoles allows the access to a wide variety of 2,4- or 2,3,4-regioselectively functionalized indoles in good overall yields. As no efficient synthetic routes to 2,3-dihaloanilines have been described in the literature, different approaches

  已经证明2，3-二卤代苯胺是用于合成4-卤代-1 H-吲哚的有用的起始原料。所制备的卤代吲哚的随后或原位官能化使得能够以良好的总收率获得各种2,4-或2,3,4-区域选择性官能化的吲哚。由于在文献中没有描述制备2，3-二卤代苯胺的有效合成途径，因此现在提出了制备这些1,2,3-官能化的芳族前体的不同方法。最一般的涉及从相应的2，3-二卤代苯酚的Smiles重排，并允许以直接且合成上有用的方式制备2，3-二卤代苯胺。
• Compounds and Uses Thereof - 849
  申请人：Arriza Jeffery Louis

  公开号：US20080318925A1

  公开（公告）日：2008-12-25

  This invention relates to the use of compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions in treating schizophrenia.

  本发明涉及使用具有以下结构式I的化合物及其药用可接受的盐、互变异构体或体内可水解的前体，在治疗精神分裂症方面的组合物。
• Substituted-8-alkenyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic
  申请人：American Home Products

  公开号：US04822781A1

  公开（公告）日：1989-04-18

  Indole derivatives characterized by having a 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid nucleus bearing substituents in position 1-, 5-, 6-, 7- and 8- are disclosed. The derivatives are useful anti-inflammatory and/or analgesic agents. Methods for their preparation and use are also disclosed.

  本发明揭示了一种以1,3,4,9-四氢吡喃[3,4-b]吲哚-1-乙酸核为特征，其在1-、5-、6-、7-和8-位置带有取代基的吲哚衍生物。这些衍生物是有用的抗炎和/或镇痛剂。同时还揭示了它们的制备和使用方法。
• Tricyclic steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696130A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了高亲和力、高选择性的非甾体化合物，用于调节甾体受体。还公开了包含这些化合物的药物组合物，以及使用所公开的化合物和组合物治疗需要甾体受体激动剂或拮抗剂治疗的患者的方法，有用于制备这些化合物的中间体和制备甾体受体调节剂化合物的过程。
• Steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696133A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiting steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了一种高亲和力、高选择性的非甾体化合物，用于调节甾体受体。还公开了包含这些化合物的制药组合物，使用所公开的化合物和组合物治疗需要甾体受体激动剂或拮抗剂治疗的患者的方法，用于制备这些化合物的中间体以及制备甾体受体调节剂化合物的方法。